CA2968980A1 - Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same - Google Patents

Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same Download PDF

Info

Publication number
CA2968980A1
CA2968980A1 CA2968980A CA2968980A CA2968980A1 CA 2968980 A1 CA2968980 A1 CA 2968980A1 CA 2968980 A CA2968980 A CA 2968980A CA 2968980 A CA2968980 A CA 2968980A CA 2968980 A1 CA2968980 A1 CA 2968980A1
Authority
CA
Canada
Prior art keywords
hepe
agent
fibrosis
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2968980A
Other languages
English (en)
French (fr)
Inventor
Jonathan Rowe
Kevin Duffy
John Climax
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afimmune Ltd
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of CA2968980A1 publication Critical patent/CA2968980A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2968980A 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same Abandoned CA2968980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
US62/086,535 2014-12-02
PCT/US2015/063488 WO2016090030A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (1)

Publication Number Publication Date
CA2968980A1 true CA2968980A1 (en) 2016-06-09

Family

ID=56092410

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2968980A Abandoned CA2968980A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Country Status (17)

Country Link
US (1) US10363235B2 (enExample)
EP (2) EP3226873B1 (enExample)
JP (2) JP6986445B2 (enExample)
KR (1) KR20170102879A (enExample)
CN (2) CN107206008A (enExample)
AU (2) AU2015358512B2 (enExample)
BR (1) BR112017011685A2 (enExample)
CA (1) CA2968980A1 (enExample)
ES (1) ES2900593T3 (enExample)
IL (2) IL252431B (enExample)
MA (1) MA41120A (enExample)
MX (2) MX382116B (enExample)
PH (1) PH12017501022B1 (enExample)
RU (2) RU2020115523A (enExample)
SG (2) SG11201704495VA (enExample)
WO (1) WO2016090030A1 (enExample)
ZA (2) ZA201704463B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
CN107405324A (zh) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 包含15‑hepe的组合物和其使用方法
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU2634101A (en) * 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
JP2010500566A (ja) * 2006-08-08 2010-01-07 テシス バイオサイエンス， インコーポレイテッド 非アルコール性脂肪肝疾患（ｎａｆｌｄ）および非アルコール性脂肪性肝炎（ｎａｓｈ）のマーカーおよびその使用方法
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same

Also Published As

Publication number Publication date
IL252431B (en) 2021-12-01
MX2021005080A (es) 2021-06-15
PH12017501022B1 (en) 2022-02-16
EP3226873B1 (en) 2021-10-27
PH12017501022A1 (en) 2017-11-27
HK1245101A1 (zh) 2018-08-24
MA41120A (fr) 2017-10-10
AU2021203189A1 (en) 2021-06-10
AU2015358512B2 (en) 2021-02-18
MX2017007000A (es) 2017-12-07
CN112245419A (zh) 2021-01-22
RU2017122758A3 (enExample) 2019-06-13
JP2017536380A (ja) 2017-12-07
AU2015358512A1 (en) 2017-07-20
EP3226873A4 (en) 2018-08-08
IL252431A0 (en) 2017-07-31
WO2016090030A1 (en) 2016-06-09
EP3988101A1 (en) 2022-04-27
RU2721555C2 (ru) 2020-05-20
ES2900593T3 (es) 2022-03-17
KR20170102879A (ko) 2017-09-12
BR112017011685A2 (pt) 2018-01-02
CN107206008A (zh) 2017-09-26
MX382116B (es) 2025-03-13
IL287983A (en) 2022-01-01
US20160184252A1 (en) 2016-06-30
JP6986445B2 (ja) 2021-12-22
EP3226873A1 (en) 2017-10-11
JP2022031813A (ja) 2022-02-22
ZA201804380B (en) 2021-03-31
RU2017122758A (ru) 2019-01-09
US10363235B2 (en) 2019-07-30
ZA201704463B (en) 2018-11-28
SG11201704495VA (en) 2017-06-29
SG10202010594WA (en) 2020-12-30
RU2020115523A (ru) 2021-01-27

Similar Documents

Publication Publication Date Title
US10363235B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
KR102434817B1 (ko) 15-hepe를 포함하는 조성물 및 그의 사용 방법
US12017986B2 (en) Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
KR20200055154A (ko) 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
HK1245101B (en) Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis
US20210085627A1 (en) Methods of treating diseases and disorders using compositions comprising 18-hepe, 12-hepe, or combinations thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201124

FZDE Discontinued

Effective date: 20230612